



NEXUS – All you want to know about IHI and upcoming calls (Call 13)

24.09.2026 • Geraldine Joanny • Pamplona



Outline of the presentation

- IHI in a nutshell
- Future funding opportunities: introducing IHI Call 13
- Two-stage calls: how does it work

An abstract graphic on the left side of the slide. It consists of three vertical rounded rectangles of varying heights and positions. The first rectangle is on the far left, the second is in the middle, and the third is on the right. A small green dot is located on the rightmost rectangle, approximately in the middle vertically.

IHI in a nutshell



Bold collaborations, transforming health




We are a public-private partnership...

The partners contribute equally to our €2.4 billion budget

Public

EU (Horizon Europe)

Funds go to: research
orgs, SMEs, patients,
healthcare, regulators...



Industry members

In-kind or financial contribution




Contributing partners

In-kind or financial contribution


Private

... and so are our projects ...



Collaboration is part of our DNA

IHI's purpose – from objectives to impacts



PILLAR II
Global challenges & European industrial competitiveness

PILLAR III
Innovative Europe

CLUSTER 1: Health	CLUSTER 4: Digital, industry and space	CLUSTER 5: Climate, energy and mobility	CLUSTER 6: Food, bioeconomy, natural resources, agriculture and environment	EUROPEAN INNOVATION ECOSYSTEMS
Innovative Health Initiative	Chips (formerly KDT)	Clean Hydrogen	Circular Bio-based Europe	Innovative SMEs
Global Health Partnership	Smart Networks & Services	Clean Aviation	R&I in the Mediterranean Area (PRIMA) (Art. 185)**	
Transformation of Health and Care Systems	High Performance Computing	Single European Sky ATM Research 3	Biodiversa+	EIT
Chemicals Risk Assessment	European Metrology (Art. 185)	Europe's Rail	Climate Neutral, Sustainable & Productive Blue Economy	InnoEnergy
ERA for Health	AI-Data-Robotics	Connected, Cooperative and Automated Mobility (CCAM)	Water4All	Climate
Rare Diseases*	Photonics	Batt4EU	Animal Health and Welfare	Digital
Personalised Medicine	Made in Europe	Zero-emission waterborne transport	Accelerating Farming Systems Transitions	Food
One-Health Anti Microbial Resistance*	Clean Steel – Low-Carbon Steelmaking	Zero-emission road transport	Agriculture of Data*	Health
Pandemic Preparedness*	Processes4Planet	Built4People	Safe and Sustainable Food System	Raw Materials
	Globally Competitive Space Systems*	Clean Energy Transition		Manufacturing
		Driving Urban Transitions		Urban Mobility
				Cultural and Creativity*

■ Institutionalised Partnerships (Art. 185/7)

■ Institutionalised Partnerships / EIT KICs

■ Co-programmed


■ Co-funded

* Partnership not yet launched

** Direct continuation of a H2020 partnership

Source: European Commission

Horizon Europe – European Partnerships to be implemented as joint undertakings



To strengthen the impact of European Partnerships, the Horizon Europe 2028-2034 proposal suggests **streamlining implementation modes** and using a **portfolio approach to identify a limited set of coherent partnerships**, with objectives **closely aligned with the European Competitiveness Fund**. Under this initiative, some European Partnerships will be implemented as joint undertakings in accordance with Article 187 TFEU, with clear added value, through a single establishing act with harmonised rules.

Consultation



**Have your say
on the future of
European
partnerships in
research and
innovation!**



16 October 2026



[Access the consultation](#)

✓ If you are a stakeholder in the health field, this is your opportunity to share your experience and views on how European partnerships can continue addressing the complex, multistakeholder and system-level shifts required to support the healthcare of tomorrow.


Why does it matter?

In a context where all funding instruments are under close scrutiny, the consultation is important because the results will contribute to the design of the future European partnership landscape in the health field, and how joint undertakings will work in practice.

What happens next?

The results of the consultation will feed into the European Commission's wider impact assessment on European partnerships and ultimately into a proposal for a single basic act (SBA) setting up joint undertakings under the next Horizon Europe programme. The Commission expects to publish the legislative proposal at the end of 2026 or early 2027.






The IHI portfolio



SO1 – Understand Disease | SO2 – Integrated Solution | SO3 – Patient-Centricity | SO4 – Digital Health & AI | SO5 – Value Assessment

(IHI grant agreements from Call 1 to 9)

What are our projects delivering?





● Participation of Navarrese entities in IHI

Universidad De Navarra (University)

- **ACCESS-AD**

Advancing clinical care and equity through scalable solutions in Alzheimer's disease diagnosis and treatment

Total project budget: € 34 336 647

EU funding to this participant: € 603 771

- **COMPASS**

Cardio-oncology multidisciplinary patient assistance solution

Total project budget: € 52 233 017

EU funding to this participant: € 350 000

- **EASYGEN**

Easy workflow integration for gene therapy

Total project budget: € 13 991 874

EU funding to this participant: € 352 750

Zabala Innovation Consulting SA (SME)

- **COMPASS**

Cardio-oncology multidisciplinary patient assistance solution

Total project budget: € 52 233 017

EU funding to this participant: € 729 945

- **READI**

REpresentative Clinical Research - ADvancing Inclusivity in Europe

Total project budget: € 68 240 874

EU funding to this participant: € 796 280

Participation of Navarrese entities: IHI Easygen



EASYGEN is a European research project developing a modular platform for hospital-based CAR-T manufacturing.

Universidad de Navarra

Pamplona, Spain

The University of Navarra conducts academic and industry-sponsored clinical trials with CAR-T cells. Our work focuses on optimizing CAR-T production through novel designs, new targets, and non-viral delivery methods. We monitor clinical samples, study mechanisms of CAR-T cell response and resistance, and perform genomic, transcriptomic, and gene editing research to advance cellular therapies.

WP2 - Process management

WP4 - Market readiness

WP5 - Regulatory

WP7 - Next-gen CAR-T

WP8 - Hospital deployment



**Prof.
Felipe Prósper
Cardoso, MD, PhD**
Head of Cellular Therapy
Unit

[Learn more](#)



**Susana Inogés
Sancho, MD, PhD**
Specialist in Immunology

[Learn more](#)



**Ascensión López Díaz
de Cerio, PhD**
Clinical Research Associate

[Learn more](#)



**Assoc. Prof.
Juan Roberto
Rodríguez Madoz, PhD**
Researcher

[Learn more](#)



IHI funding opportunities: Introducing Call13



IHI call 13

deadline 8 October 2026

1. A network to boost the new wave of European innovations in healthcare
2. An AI foundation toxicology model and framework to support waiving a second species in drug safety studies
3. Decode the immuno-science of age-related immune-mediated diseases






2-stage calls: How does it work



How do two-stage calls work?





Important consideration

- Remember: the pre-identified industry consortium and contributing partner(s) if any listed in the call topic text will join at stage 2 the first-ranked applicant consortium.
- Applicants should therefore already consider the expected contributions from the pre-identified industry consortium and contributing partner(s) in their proposals in order to successfully enable a public-private partnership.



Points to remember

- Read all the call-relevant material: www.ihl.europa.eu
- We expect strong competition: high quality of proposal is a must.
- Ensure that all information is explicitly described in order to allow the expert-evaluators to assess against the evaluation sub-criteria. **Respect the page limit**
- Use the **proposal structure / template**



Your contact point



At the IHI Programme Office



General queries:
applicants@ihi.europa.eu



Stay in touch



Visit us

www.ihieuropa.eu




Write to us

infodesk@ihieuropa.eu



Sign up
for our newsletter



Connect with us



LinkedIn

Innovative Health
Initiative (IHI)



Bluesky

[@ihieurope.bsky.social](https://bsky.app/profile/@ihieurope.bsky.social)



Mastodon

[@IHIEurope@mastodon.social](https://mastodon.social/@IHIEurope)



Thank you for your attention

